We use cookies to help us improve the website and your experience using it. You may delete and block all cookies from this site at any time. However, please note this may result in parts of the site no longer working correctly. If you continue without changing your settings we will assume you are happy to receive all cookies on this site.


Beta 2 Glycoprotein (IgG and IgM)

General information

Anti-phospholipid syndrome (APS) is an acquired autoimmune condition. The clinical features are venous, arterial and microvascular thrombosis and/or pregnancy complications. Testing for β2GP1 antibodies can be helpful for APS diagnosis, particularly when anti-cardiolipin antibodies and lupus anticoagulant are negative and APS is strongly suspected.

Specimen transport: At room temperature

Repeat frequency: The British Society for Standards Clinical Haematology guidelines requires anti-cardiolipin, lupus anticoagulant or Anti-β2-glycoprotein I to be present on two or more occasions at least 12 weeks apart to diagnose anti-phospholipid syndrome antibody.

Special precautions: None

Laboratory information

Reference range Normal Borderline
IgG β2GP1 0-7 kU/l 7-10 kU/l
IgM β2GP1 0-7 kU/l 7-10 kU/l

Volume and sample type: 7ml clotted blood

Method: FEIA (Fluoroenzyme Immunoassay)

Turnaround time (calendar days from sample receipt to authorised result): Median: 1, 95th percentile - 4

EQA scheme: UK NEQAS Scheme for Phospholipid antibodies.

Clinical information

Indications for the test: This test should be used when investigating a patient for anti-phospholipid syndrome. The clinical features of anti-phospholipid syndrome are detailed above.

Factors affecting the test: β2GP1 antibodies should not be relied upon as a diagnostic tool but must be used in conjunction with evaluation of clinical, pathological and imaging features.


(Last updated July 11th 2016)